Art

J-GLOBAL ID：201802287056264007   Reference number：18A1053083

Current state of therapeutic development for rare cancers in Japan, and proposals for improvement

日本における希少がんの治療開発の現状と改善のための提案

Author (34)： Kawai Akira (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Kawai Akira (Department of Musculoskeletal Oncology and Rehabilitation, Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan) ,  Goto Toshio (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Goto Toshio (Program for Drug Discovery and Medical Technology Platforms, RIKEN, Tsukuba, Japan) ,  Shibata Tatsuhiro (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Shibata Tatsuhiro (Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan) ,  Tani Kenzaburo (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Tani Kenzaburo (Project Division of ALA Advanced Medical Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan) ,  Mizutani Shuki (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Mizutani Shuki (Tokyo Medical and Dental University, Tokyo, Japan) ,  Nishikawa Akiyoshi (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Nishikawa Akiyoshi (Biological Safety Research Center, National Institute of Health Sciences, Tokyo, Japan) ,  Shibata Taro (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Shibata Taro (Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan) ,  Matsumoto Seiichi (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Matsumoto Seiichi (Sarcoma Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan) ,  Nagata Kyosuke (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Nagata Kyosuke (University of Tsukuba, Tsukuba, Japan) ,  Narukawa Mamoru (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Narukawa Mamoru (Department of Clinical Medicine (Pharmaceutical Medicine), School of Pharmacy, Kitasato University, Sagamihara, Japan) ,  Matsui Shigeyuki (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Matsui Shigeyuki (Department of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan) ,  Ando Masashi (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Ando Masashi (Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagakute, Japan) ,  Toguchida Junya (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Toguchida Junya (Institute for Frontier Life and Medical Sciences/Center for iPS Cell Research and Application, Kyoto University, Tokyo, Japan) ,  Monden Morito (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Monden Morito (Sakai City Hospital Organization, Sakai, Japan) ,  Heike Toshio (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Heike Toshio (Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan) ,  Kimura Shinya (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Kimura Shinya (Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan) ,  Ueda Ryuzo (Subcommittee on Rare Cancers, The Science Board to the Pharmaceuticals and Medical Devices Agency, Tokyo, Japan) ,  Ueda Ryuzo (Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan)
Material： Cancer Science (Web)  (Cancer Sci (Web))
Volume： 109  Issue： 5  Page： 1731-1737  Publication year： 2018 
JST Material Number： U0505A  ISSN： 1349-7006  Document type： Article
Article type： 解説  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： *tumor ,...
Semi thesaurus term： *rare cancer ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1053083&from=J-GLOBAL&jstjournalNo=U0505A") }}

Author keywords (5)： cancer registry ,  evaluation method ,  rare cancer ,  rare subtype of cancer ,  therapeutic development

JST classification (1)： Treatment for tumors in general  (GE03031L)

Terms in the title (6)： 日本 ,  希少がん ,  治療 ,  開発 ,  現状 ,  提案